Login / Signup

Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.

Anagha GogateStephanie B WheelerKatherine E Reeder-HayesDonatus U EkwuemeTemeika L FairleySarah DrierJustin G Trogdon
Published in: JNCI cancer spectrum (2021)
The cost of mBC could increase substantially in the coming decade, especially among younger and midlife women. Although accounting for trends in incidence, progression, and survival, our model did not attempt to forecast structural changes such as technological innovations in breast cancer treatment and health-care delivery reforms. These findings can motivate early detection activities, direct value-driven mBC treatment, and provide a useful baseline against which to measure the effect of prevention and treatment efforts.
Keyphrases
  • healthcare
  • metastatic breast cancer
  • risk factors
  • type diabetes
  • polycystic ovary syndrome
  • combination therapy
  • adipose tissue
  • quality improvement
  • pregnant women
  • social media